Braveheart Bio
- Market cap
- 1.67B
- P/E (TTM)i
- -3.01
- P/Bi
- -17.45
- EPSi
- -0.94
- Div yieldi
- 0.00%
- 52W posi
- 1%
Anonymous reader poll. Unscientific, not investment advice.
Braveheart Bio shares were changing hands at 18.58, down 6.11% on the day. At current prices, the business is worth about 1.67B, the #2845 most valuable US-listed company we track. The 5 analysts covering the stock are, on balance, at Buy, targeting an average of 45.25 (+144%). Against a 52-week band of 18.47-32.00, the shares are currently 1% of the way up.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Main-fund capital flow has been a net outflow over the last 42 sessions.
- Short interest has risen to 2.7% of float.
- Analyst tilt is Buy.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Key statistics
Price & volume
- Prev close
- 19.79
- Open
- 19.61
- Day range
- 18.47 - 19.65
- Avg price
- 18.82
- Volume
- 336.95K
- Turnover
- 6.34M
- Turnover ratei
- 1.80%
- Volume ratioi
- 0.47
- Amplitudei
- 5.94%
- 52-week rangei
- 18.47 - 32.00
Valuation
- P/Ei
- -19.87
- P/E (TTM)i
- -3.01
- P/Bi
- -17.45
- EPSi
- -0.94
- Book value / shi
- -1.07
- Net profit
- -84.19M
- Net assets
- -95.89M
Share structure
- Market cap
- 1.67B
- Float capi
- 348.38M
- Shares out
- 90.04M
- Float sharesi
- 18.75M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-08-06
41.9% below the 52-week high
Trading activity
Net capital flow main funds, last 42 sessions
-1.64M net over the window
Short interest
- Shares short
- 2.46M
- % of floati
- 2.73%
- Days to coveri
- 7.49
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Braveheart Bio (BRVE)?
Braveheart Bio last traded at 18.58. The quote on this page refreshes every few seconds while US markets are open.
What is Braveheart Bio's market cap?
About 1.67B.
What is the P/E ratio of Braveheart Bio?
The trailing twelve-month P/E is -3.01. The Valuation tab shows it against the stock's own five-year range.
Does Braveheart Bio pay a dividend?
Braveheart Bio does not currently pay a regular dividend.
Is Braveheart Bio a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 45.25, which implies 143.5% upside from the current price. This is not investment advice.
What is Braveheart Bio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Braveheart Bio a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.